Your browser doesn't support javascript.
loading
To Prescribe or Not to Prescribe?: Barriers and Motivators for Progressing Along Each Stage of the Buprenorphine Training and Prescribing Path.
Winograd, Rachel P; Coffey, Bridget; Woolfolk, Candice; Wood, Claire A; Ilavarasan, Vinith; Liss, David; Jain, Subodh; Stringfellow, Erin.
Afiliação
  • Winograd RP; St. Louis - Missouri Institute of Mental Health, University of Missouri, 43 Benton Court, St. Louis, MO, 63121, USA. rachel.winograd@umsl.edu.
  • Coffey B; St. Louis - Missouri Institute of Mental Health, University of Missouri, 43 Benton Court, St. Louis, MO, 63121, USA.
  • Woolfolk C; St. Louis - Missouri Institute of Mental Health, University of Missouri, 43 Benton Court, St. Louis, MO, 63121, USA.
  • Wood CA; St. Louis - Missouri Institute of Mental Health, University of Missouri, 43 Benton Court, St. Louis, MO, 63121, USA.
  • Ilavarasan V; St. Louis - Missouri Institute of Mental Health, University of Missouri, 43 Benton Court, St. Louis, MO, 63121, USA.
  • Liss D; Department of Emergency Medicine, Washington University School of Medicine, 660 S Euclid Ave, St. Louis, MO, 63110, USA.
  • Jain S; Spectrum Health, Division of Psychiatry and Behavioral Medicine, 2750 E Beltline NE, Grand Rapids, MI, 49525, USA.
  • Stringfellow E; Massachusetts General Hospital Institute for Technology Assessment & Harvard Medical School, Boston, MA, USA.
J Behav Health Serv Res ; 50(2): 165-180, 2023 04.
Article em En | MEDLINE | ID: mdl-35060002
This study aimed to identify the strongest barriers and motivators associated with each step toward buprenorphine prescribing (1. obtaining a waiver, 2. beginning to prescribe, and 3. prescribing to more people) among a sample of Missouri-based medical professionals (N = 130). Item weights (number of endorsements times mean rank of the item's importance) were calculated based on their responses. Across groups, lack of access to psychosocial support services, need for higher levels of care, and clinical complexity were strong barriers. Among non-prescribers (n = 57, 46.3%), administrative burden, potential of becoming an addiction clinic, and concern about misuse and diversion were most heavily weighted. Among prescribers (n = 66, 53.7%), patients' inability to afford medications was a barrier across phases. Prominent motivators among all groups were the effectiveness of buprenorphine, improvement in other health outcomes, and a personal interest in treating addiction. Only prescribers reported the presence of institutional support and mentors as significant motivators.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Buprenorfina / Comportamento Aditivo / Transtornos Relacionados ao Uso de Opioides Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Buprenorfina / Comportamento Aditivo / Transtornos Relacionados ao Uso de Opioides Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article